Cargando…
Assessment of Dosing and Patient Factors on the Efficacy of Warfarin Following Total Joint Replacement
The purpose of this study was to determine the percentage of patients discharged with a subtherapeutic INR <1.8 using our institutions inpatient warfarin dosing nomogram following total joint arthroplasty (TJA). We examined predisposing risk factors for a subtherapeutic discharge (INR <1.8), i...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Bentham Open
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4483539/ https://www.ncbi.nlm.nih.gov/pubmed/26157529 http://dx.doi.org/10.2174/1874325001509010129 |
_version_ | 1782378578793463808 |
---|---|
author | Murphy, Ryan Stehli, Annamarie Nguyen, Hiep Leu, Szu-Yun Nguyen, Danh V Schwarzkopf, Ran |
author_facet | Murphy, Ryan Stehli, Annamarie Nguyen, Hiep Leu, Szu-Yun Nguyen, Danh V Schwarzkopf, Ran |
author_sort | Murphy, Ryan |
collection | PubMed |
description | The purpose of this study was to determine the percentage of patients discharged with a subtherapeutic INR <1.8 using our institutions inpatient warfarin dosing nomogram following total joint arthroplasty (TJA). We examined predisposing risk factors for a subtherapeutic discharge (INR <1.8), including increased body weight, age, gender, end stage renal disease (ESRD), smoking, and peri-operative transfusion. Chart review identified 249 patients for study inclusion. Logistic regression (LR) was used to identify associated risk factors for a subtherapeutic INR (<1.8) on day of discharge. The majority of patients (58.6%, 146 of 249) following TJA surgery were found to have a subtherapeutic INR level (INR<1.8) at discharge (mean length of stay 2.6 days). Multivariate LR analysis found that weight greater than 180 lbs. (OR 2.08, CI 1.09, 3.98, P=0.027) was found to increase the odds of a subtherapeutic INR on day of discharge. Our results were not significant for weight 20% beyond ideal body weight, age (>65y), gender, peri-operative transfusion, smoking, ESRD or autoimmune disease. A patient’s body weight influences response to warfarin following TJA. An inpatient warfarin dosing nomogram that takes into account a patient’s weight should be used to reduce the risk of subtherapeutic INR levels in obese TJA patients. |
format | Online Article Text |
id | pubmed-4483539 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Bentham Open |
record_format | MEDLINE/PubMed |
spelling | pubmed-44835392015-07-08 Assessment of Dosing and Patient Factors on the Efficacy of Warfarin Following Total Joint Replacement Murphy, Ryan Stehli, Annamarie Nguyen, Hiep Leu, Szu-Yun Nguyen, Danh V Schwarzkopf, Ran Open Orthop J Article The purpose of this study was to determine the percentage of patients discharged with a subtherapeutic INR <1.8 using our institutions inpatient warfarin dosing nomogram following total joint arthroplasty (TJA). We examined predisposing risk factors for a subtherapeutic discharge (INR <1.8), including increased body weight, age, gender, end stage renal disease (ESRD), smoking, and peri-operative transfusion. Chart review identified 249 patients for study inclusion. Logistic regression (LR) was used to identify associated risk factors for a subtherapeutic INR (<1.8) on day of discharge. The majority of patients (58.6%, 146 of 249) following TJA surgery were found to have a subtherapeutic INR level (INR<1.8) at discharge (mean length of stay 2.6 days). Multivariate LR analysis found that weight greater than 180 lbs. (OR 2.08, CI 1.09, 3.98, P=0.027) was found to increase the odds of a subtherapeutic INR on day of discharge. Our results were not significant for weight 20% beyond ideal body weight, age (>65y), gender, peri-operative transfusion, smoking, ESRD or autoimmune disease. A patient’s body weight influences response to warfarin following TJA. An inpatient warfarin dosing nomogram that takes into account a patient’s weight should be used to reduce the risk of subtherapeutic INR levels in obese TJA patients. Bentham Open 2015-05-15 /pmc/articles/PMC4483539/ /pubmed/26157529 http://dx.doi.org/10.2174/1874325001509010129 Text en © Murphy et al.; Licensee Bentham Open. http://creativecommons.org/licenses/by-nc/3.0/ This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited. |
spellingShingle | Article Murphy, Ryan Stehli, Annamarie Nguyen, Hiep Leu, Szu-Yun Nguyen, Danh V Schwarzkopf, Ran Assessment of Dosing and Patient Factors on the Efficacy of Warfarin Following Total Joint Replacement |
title | Assessment of Dosing and Patient Factors on the Efficacy of Warfarin Following Total Joint Replacement |
title_full | Assessment of Dosing and Patient Factors on the Efficacy of Warfarin Following Total Joint Replacement |
title_fullStr | Assessment of Dosing and Patient Factors on the Efficacy of Warfarin Following Total Joint Replacement |
title_full_unstemmed | Assessment of Dosing and Patient Factors on the Efficacy of Warfarin Following Total Joint Replacement |
title_short | Assessment of Dosing and Patient Factors on the Efficacy of Warfarin Following Total Joint Replacement |
title_sort | assessment of dosing and patient factors on the efficacy of warfarin following total joint replacement |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4483539/ https://www.ncbi.nlm.nih.gov/pubmed/26157529 http://dx.doi.org/10.2174/1874325001509010129 |
work_keys_str_mv | AT murphyryan assessmentofdosingandpatientfactorsontheefficacyofwarfarinfollowingtotaljointreplacement AT stehliannamarie assessmentofdosingandpatientfactorsontheefficacyofwarfarinfollowingtotaljointreplacement AT nguyenhiep assessmentofdosingandpatientfactorsontheefficacyofwarfarinfollowingtotaljointreplacement AT leuszuyun assessmentofdosingandpatientfactorsontheefficacyofwarfarinfollowingtotaljointreplacement AT nguyendanhv assessmentofdosingandpatientfactorsontheefficacyofwarfarinfollowingtotaljointreplacement AT schwarzkopfran assessmentofdosingandpatientfactorsontheefficacyofwarfarinfollowingtotaljointreplacement |